THE EFFICACY OF COMBINED BIOMARKER TESTS IN EARLY DIAGNOSTICS OF ACUTE MYOCARDIAL INFARCTION AFTER CLINICAL SYMPTOMS ONSET: ROLE OF HEART-TYPE FATTY ACID-BINDING PROTEIN

Aim. To evaluate the diagnostic value of heart-type fatty acid-binding protein (H-FABP) introduction to standard cardiac biomarkers in diagnostics of myocardial infarction (MI) early after clinical symptoms onset. Material and methods. Patients aged 18 years and older admitted to the hospital with acute coronary syndrome (ACS) during first 6 hours after ACS symptoms onset were enrolled into the study. At hospitalization level of biomarkers of myocardial damage (creatine phosphokinase-MB fraction - CPK-MB, troponin T) and qualitative tests on FABP were assessed in all patients. Serum troponin T concentration measured in 12 hours after the hospitalization was used to confirm diagnosis of MI. Moreover , diagnosis of MI was verified by echocardiography with the assessment of local reduction in myocardial contractility. Results. 101 patients were included into the study (27% female; aged 59.9±12.4). At the moment of hospitalization 71 (70%) patients were diagnosed with ACS with ST-segment elevation, and 30 (30%) patients - ACS without ST-segment elevation. In total, period between clinical symptoms onset and hospitalization was 3.6±1.4 hours. Analysis of diagnostic value of tests during the first 6 hours after ACS symptoms onset showed higher sensitivity of H-FABP in comparison with troponin T and CPK-MB (72.5, 56.2 and 49.5%, respectively). Specificity of these tests during the first 6 hours after onset of clinical signs of ACS was 90, 100 и 90%, respectively.  Sensitivity and specificity were 87.7 and 100.0%, respectively , when H-FABP , troponin T and CPK-MB were used in combination as a “block test” in patients hospitalized during the first 6 hours after ACS symptoms onset. Sensitivity and specificity were 74.3 и 100.0%, respectively , when “block test” was used in patients hospitalized during the first 3 hours after ACS symptoms onset; between 3 and 6 hours after ACS symptoms onset sensitivity and specificity of tests reached 100%. Conclusion. “Block test” with H-FABP , troponin T and CPK-MB early after ACS symptoms onset is more sensitive in comparison with separate use of the tests.

1. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012; 125: e2—e220.

2. Thygesen K., Alpert J.S., White H.D., et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634—2653.

3. Thygesen K., Alpert J.S., White H.D. Universal definition of myocardial infarction. J Am Coll Cardiol 2007; 50: 2173—2195.

4. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598—1660.

5. Glatz J., van der Vusse G., Simoons M., et al. Fatty acid–binding protein and the early detection of acute myocardial infarction. Clinica Chimica Acta 1998; 272: 87—92.

6. O'Donoghue M., deLemos J., Morrow D., et al. Prognostic utility of heart-type FABP in patients with acute coronary syndromes. Circulation 2006;114: 550—557.

7. Tanaka T., Hirota Y., Sohmiya K., et al. Serum and urinary human h-FABP in acute myocardial infarction. Clin Biochem 1991; 24: 195—201.

8. Kilcullen N., Viswanathan K., Das R., et al. Heart-type fatty acid binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. J Am College Cardiology 2007; 50: 2061—2067.

9. Morrow D.A., Cannon C.P., Jesse R.L., et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 2007; 53: 552—574.

10. McMahon C.G., Lamont J.V., Curtin E., et al. Diagnostic accuracy of heart-type fatty acid-binding protein for the early diagnosis of acute myocardial infarction. Am J Emerg Med 2012; 30: 267—274.

11. Golovenkin S.E., Shul'man V.A., Pelipetskaya E.Yu., et al. The use of rapid test "KardioBSZhK" for the early diagnosis of myocardial necrosis in patients with acute coronary syndrome. Spravochnik Vracha Ob-shchey Praktiki 2012; (1); 29—40. Russian (Головенкин С.Е., Шульман В.А., Пелипецкая Е.Ю., и др. Применение экспресс-теста «КардиоБСЖК» для ранней диагностики некроза миокарда у больных острым коронарным синдромом. Справочник Врача Общей Практики 2012; (1); 29—40).

12. Ryabov V.V., Suslova T.E., Markov V.A. i dr. Determination of protein and other fatty acid binding, in the diagnosis of acute myocardial infarction. Byulleten SO RAMN 2005; (3): 26—29. Russian (Рябов В.В., Суслова Т.Е., Марков В.А. и др. Определение белка, связывающего жирные кислоты, в диагностике острого инфаркта миокарда. Бюллетень СО РАМН 2005; (3): 26—29).

13. Corteville D.C., Armstrong D.F., Montgomery D.G., et al.Treatment and outcomes of first troponin-negative non-ST-segment elevation myocardial infarction. Am J Cardiol 2011; 107: 24—29.

14. Hamm C.W., Bassand J.P., Agewall S., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 2011; 32: 2999—3054.

15. Keller T., Zeller T., Ojeda F., et al. Serial Changes in Highly Sensitive Troponin I Assay and Early Diagnosis of Myocardial Infarction. JAMA 2011; 306: 2684—2693.

16. Wright R.S., Anderson J.L., Adams C.D., et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am CollCardiol 2011; 57: e215—367.

17. Figiel Ł., Wraga M., Bednarkiewicz Z., et al. Direct comparison of the diagnostic value of point-of-care tests detecting heart-type fatty acid binding protein or glycogen phosphorylaseisoenzyme BB in patients with acute coronary syndromes with persistent ST-segment elevation. Kardiol Pol 2011; 69: 1–6.

18. Van Nieuwenhoven F.A., Kleine A.H., Wodzig W.H., et al. Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid binding protein. Circulation 1995; 92: 2848—54.

19. Alhadi H.A., Fox K.A. Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid–binding protein? QJM 2004; 97: 187—198.

20. Freund Y., Chenevier-Gobeaux C., Leumani F., et al. Heart-type fatty acid binding protein and the diagnosis of acute coronary syndrome in the ED. Am J Emerg Med 2011. [Epub ahead of print].